CN101057901B - Traditional Chinese medicinal composition for curing hepatitis - Google Patents
Traditional Chinese medicinal composition for curing hepatitis Download PDFInfo
- Publication number
- CN101057901B CN101057901B CN200710037338A CN200710037338A CN101057901B CN 101057901 B CN101057901 B CN 101057901B CN 200710037338 A CN200710037338 A CN 200710037338A CN 200710037338 A CN200710037338 A CN 200710037338A CN 101057901 B CN101057901 B CN 101057901B
- Authority
- CN
- China
- Prior art keywords
- extract
- lentinus edodes
- fructus crataegi
- parts
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal composition for treating hepatitis, which is prepared from mushroom extract obtained from mushroom fruiting body, and water extract of haw through mixing homogeneously.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of hepatitis, be particularly suitable for the treatment and the prevention of fatty liver, can be used as health product or pharmaceutical applications, belong to technical field of Chinese medicines.
Background technology
Liver is lipometabolic important place, when liver increases the lipogenesis ability and/or transports the ability drop of blood, lipid material (being mainly triacylglycerol) is accumulated in liver too much, surpass 5% of liver weight, or on the histology, during the liver parenchyma fatization more than 50%, be fatty liver.Fatty liver is not an independently disease, but the liver fat change that causes by multiple disease and reason.Common cause is obesity, alcoholism, diabetes; Secondly be nutritional disorder, drug intoxication, gestation, heredity etc.
Continuous improvement along with China people material life, the sickness rate of China's fatty liver raises year by year, 10% of average population have been accounted for, fat, have a liking for spill with diabetic population in can be up to 50%～60%, hepatic fibrosis takes place in wherein about 25% patient, and 1.5%～8.0% patient develops into liver cirrhosis.Therefore, Prevention and Management of Fatty Liver is crucial to stoping the chronic hepatopathy progress and improving prognosis.
At present domestic at fatty liver treatment and prevention aspect have plurality of Chinese and chemicals available, simvastatin is wherein a kind of, its effective percentage is on the low side, and many side effect are arranged, as stomachache, constipation, flatulence etc.
Summary of the invention
The purpose of this invention is to provide a kind of effective, side effect is little, can treat and prevent, can be used as health product or medicine in order to the treatment hepatitis Chinese medicine composition.
For realizing above purpose, technical scheme of the present invention provides a kind of Chinese medicine composition for the treatment of hepatitis, it is characterized in that, is made by the raw material of following weight portion: 1～4 part of Fructus Crataegi extract, and 4～16 parts of Lentinus Edodes extract, its preparation method is:
(1) gets clean mushroom fruiting body, be ground into the fritter grain, through tap water flushing dust, throw to extracting still, add the water that Lentinus Edodes weight 15-25 doubly measures, heating up is heated to 100 ℃ of extractions, extract after 3 hours-6 hours and stop, be cooled to room temperature, discharging, liquid-solid separation, clear liquid is delivered to concentrated post and is concentrated into 3～4 times of Lentinus Edodes weight, filtering residue adds the water that 15-12 doubly measures again, repeats the said extracted condition and extracts below 6 times, and filtering residue is abandoned it, supernatant merges the 3-5 times of concentrated solution that is concentrated into mushroom fruiting body weight, at room temperature, under the stirring condition, the 2-4 that adds the concentrated solution volume doubly measures medicinal alcohol, continues to stir 20 minutes-40 minutes, after static 10 hours-14 hours, separation of supernatant reclaims ethanol, and the precipitation material is after centrifuge is centrifugal, add 1-3 and doubly measure medicinal alcohol, blend washing, again after centrifuge is centrifugal, 40 ℃ of-80 ℃ of vacuum dryings of centrifugal material drying machine, discharging, pulverize, with 60 orders/time sub-sieve sieve, promptly get Lentinus Edodes extract after the weighing;
(2) Fructus Crataegi of learning from else's experience and cutting into slices adds 8-12 times of water of Fructus Crataegi weight, decocts 2 times-4 times, each 1 hour-3 hours, collecting decoction filters, and placing spends the night makes precipitation, getting supernatant concentrates to concentrating the post, 40 ℃ of-80 ℃ of vacuum dryings of drying machine, discharging is pulverized, with 60 orders/time sub-sieve sieve, promptly get Fructus Crataegi extract;
(3) get 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract,, add microcrystalline Cellulose 90-110 part, lactose 40-60 part, magnesium stearate 1-3 part, carboxymethyl starch sodium 3-6 part, mixing, the system granule, tabletting promptly gets tablet;
(4) or 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract add microcrystalline Cellulose 90-110 part, lactose 40-60 part, and magnesium stearate 1-3 part, mixing, the system granule is filled, and promptly gets capsule;
(5) or 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract add dextrin 90-110 part, mixing, and the system granule promptly gets granule;
(6) or 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract add water 90-110 part, acesulfame-K 1-3 part, and mixing, fill promptly gets oral liquid.
Described microcrystalline Cellulose is microcrystalline Cellulose PH102.
Fructus Crataegi, the another name red fruit is the fruit of Rosaceae machaka Fructus Crataegi.Fructus Crataegi contains tartaric acid, citric acid, Crataegolic acid, neat pier acid, Quercetin, lactone, glycoside, lipolytic enzyme, flavonoid and saccharide etc.Its slightly warm in nature, sour in the mouth, sweet; Go into spleen, stomach, Liver Channel.Promoting digestion and removing stagnation, function of promoting blood circulation to disperse blood clots are arranged.
Modern study shows that Fructus Crataegi can increase the secretion of enzyme in the stomach, facilitating digestion, and contained lipolytic enzyme can promote the digestion of fat food, clothes can reduce serum cholesterol for a long time; Fructus Crataegi energy blood vessel dilating, coronary blood flow increasing brings high blood pressure down; Crataegolic acid also has cardiotonic.So can treat hypertension, coronary heart disease and hyperlipidemia etc.Fatty liver is one of common clinical, belongs to categories such as " hypochondriac pain ", " stagnation of liver-QI ".Say that according to theory of Chinese medical science its main etiology and pathology is due to the stagnation of blood stasis, so can Fructus Crataegi be main, the treatment fatty liver be used as medicine.
Lentinus Edodes is that the traditional famous food of China has bacterium, in the world artificial domesticating cultivation the earliest.Lentinus Edodes is nutritious, and delicious flavour is regarded as " king in the mushroom ".Contain protein 18.64% in the dried thin mushroom, fat 4.8%, carbohydrate 71%, in ten several amino acids that Lentinus Edodes contains, the aminoacid that 7 kinds of needed by human such as isoleucine, lysine, phenylalanine, methionine, threonine, valine are arranged also contains vitamin D, B1, B2, PP and mineral salt and crude fibre etc.In the majority with hemicellulose in the carbohydrate in the Lentinus Edodes, main component is mannitol, trehalose and bacterium sugar (mycose), glucose, pentosan, methylpentosan etc.Because the Lentinus Edodes delicious flavour is nutritious, therefore become the often edible mushroom of people.
The health care of Lentinus Edodes is worth higher: it is very high 1, to contain unsaturated fatty acid in the Lentinus Edodes, also contains the ergosterol and the fungisterol of a large amount of changed into vitamin D, for strengthening anti-disease and preventing cold and controlling preface good result is arranged.2, often edible for want of vitamin D and the serium inorganic phosphorus that causes, rickets that the blood calcium dysbolismus causes are useful to prevention human body, particularly baby, can prevent various mucosas of human body and dermatitis disease.3, contained Lentinus Edodes is given birth to very much (lentysin) and can be prevented sclerosis of blood vessels in the Lentinus Edodes, can reduce people's blood pressure.4, from Lentinus Edodes, also isolate the composition (C of serum cholesterol-lowering
8H
11O
4N
5, C
9H
11O
3N
5).5, contain a large amount of potassium salt and other mineral element in the Lentinus Edodes ash, be regarded as the ultimate food that prevents that acidic food is poisoned.
Lentinus Edodes has very high medical value, as far back as the medical value of oneself record Lentinus Edodes of China " daily vegetation " in 1329, points out that Lentinus Edodes has the merit of " QI invigorating is not hungry, controls the wind removing blood stasis ".Japan did more research to the therapeutical effect of Lentinus Edodes afterwards, proposed the growth that Lentinus Edodes can help child's skeleton and tooth, and control baby rickets promotes the health normal development.In the middle period 70 year last century, scientific and technological circle have set foot on the track that lentinan is carried out modern scientific research.According to Dehoratius, hepatitis B patient has the T cell to reduce, the phenomenon that its conversion ratio reduces.After the lentinan treatment, these phenomenons can be improved.(Ishimura etc.) find that the earliest lentinan can suppress the growth of tumor S-180 fully, and finding has plasma cell and macrophage to assemble around the tumor kitchen range, illustrate but tumor and immunologically competent cell are closely related.These data prove that tentatively lentinan has the raising immunologic function, and play tumor-inhibiting action by this function.Prove by experiment also during this that lentinan can promote glucose glycogen biosynthesis in the blood, blood sugar lowering is not only treated diabetes but also is protected the liver.
Modern study shows, contained lentinan and double stranded RNA in the Lentinus Edodes extract has stronger immunological enhancement, and fatty liver and liver cirrhosis etc. is had dietetic therapy and preventive effect.
The present invention is directed to prior art, the Chinese medicine composition that provides combines the immune enhancing ingredients in the degreasant effective ingredient of antiinflammatory and Lentinus Edodes in the Fructus Crataegi, plays the particularly effect of fatty liver of better anti-hepatitis.
But advantage of the present invention is a medicine food dual-purpose, both can treat disease, again can prevent disease; Both can pharmacy, can cook health product again.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
Embodiment 1
(1) Jie Jing mushroom fruiting body is ground into the fritter grain of 1 * 1cm.Through tap water flushing dust, throw to extracting still, add the water of 20 times of amounts of Lentinus Edodes weight, heat up and be heated to 100 ℃ of extractions, extraction stops after 4 hours.Be cooled to room temperature, discharging, liquid-solid separation, clear liquid is delivered to concentrated post and is concentrated.Filtering residue adds the water of 15 times of amounts again, repeats the said extracted condition and extracts, and repeats altogether to extract 4 times, and filtering residue is abandoned it.Supernatant merges 4 times of volume concentrated solutions that are concentrated into mushroom fruiting body weight, under room temperature, stirring condition, slowly adds 3 times of amount medicinal alcohols of concentrated solution volume, continue to stir 30 minutes, after static 12 hours, separation of supernatant, reclaim ethanol, after the precipitation material is centrifugal, add 2 times of amount medicinal alcohols, blend washing, carry out again centrifugal after, 60 ℃ of vacuum dryings of centrifugal material, discharging, pulverize, with 60 orders/time sub-sieve sieve, promptly get Lentinus Edodes extract;
(2) through the Fructus Crataegi of section, add 10 times of decoctings of Fructus Crataegi weight and boil twice, 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, and concentrated, and vacuum drying is pulverized, and promptly gets Fructus Crataegi extract.Get 4 parts of Fructus Crataegi extracts, 10 parts of Lentinus Edodes extract add microcrystalline Cellulose PH102100 part, 50 parts of lactose, and 1 part of magnesium stearate, 5 parts of carboxymethyl starch sodium, mixing, the system granule, tabletting promptly gets tablet.
Embodiment 2:
With the extract among the embodiment 1, get 1 part of Fructus Crataegi extract, 8 parts of Lentinus Edodes extract add microcrystalline cellulose rope PH102100 part, 50 parts of lactose, 1 part of magnesium stearate, mixing, the system granule is filled, and promptly gets capsule.
Embodiment 3:
With the extract among the embodiment 1, get 2 parts of Fructus Crataegi extracts, 16 parts of Lentinus Edodes extract add 100 parts in dextrin, mixing, the system granule promptly gets granule.
Embodiment 4:
With the extract among the embodiment 1, get 4 parts of Fructus Crataegi extracts, 4 parts of Lentinus Edodes extract add 100 parts in water, 1 part of acesulfame-K, mixing, fill promptly gets oral liquid.
The present invention has carried out the drug effect that pharmacological evaluation is verified the Chinese medicine composition that Fructus Crataegi and Lentinus Edodes are formed.
Get 60 of SD rats, male, normally raise 1 all backs random packet: 20 of normal control groups, 40 of model group.Normal group is raised with normal feedstuff, each animal subcutaneous injection 40%CCl of model group
4Fluid (3ml/kg) is once raised with high lipid food simultaneously.Modeling is randomly drawed normal each 10 of the model group animals that reach during 6 weeks, puts to death after the fasting, calculates the heavy coefficient of liver, measures the success or not of liver fat monitoring model, and other gets the part liver and places formalin to fix, for histopathologic examination.After the model success, model group residue animal is divided into 3 groups at random, is respectively model group (0.5%CMC-Na) solution, capsule (0.4g/mlkg of the present invention
-1), simvastatin (7mg/10mlkg
-1).Each treated animal gastric infusion every day 1 time.After 4 weeks of administration, put to death animal, get liver, claim liver heavy, get the part liver and in ethanol and acetone soln, make 10% liver homogenate, get supernatant and measure liver fat.Other gets the part liver and places formalin fixing, for histopathologic examination.
Study the amount of high fat rats'liver fat: the result shows with normal group and compares, model group liver TC, TG level have extremely significantly rising, compare with model group, with simvastatin group liver TC, TG remarkable reduction is arranged all in the capsule of the present invention, and the TC of Capsules group of the present invention, TG value all are lower than the simvastatin group, and data are as shown in the table:
| TC(mmol/L) | TG(mmol/L) | |
| Normal group | 1.11 | 0.98 |
| Model group | 2.64 | 1.73 |
| Capsules group of the present invention | 1.49 | 1.28 |
| The simvastatin group | 1.76 | 1.44 |
Pathological section is the result show: normal group lobules of liver structure is clear, liver rope radial arrangement; Model group lobules of liver structure is unclear, liver rope arrangement disorder, and hepatocyte presents steatosis in various degree; Compare with model group, Capsules group of the present invention and simvastatin group morphological change all have improvement than model group.
Experimental result shows: Chinese medicine of the present invention is combined in the treatment of fatty liver can play good effect. Below by the result of one group of small-sized clinical testing, further set forth beneficial effect of the present invention:
One, physical data adopts capsule of the present invention, the patient for the treatment of from seven years old to eight teen ages, select case 100 routine patients complete and that meet diagnostic criteria to observe. Now the result is added up.
Two, methods for the treatment of is taken medicine 3 times every day, and 23 days is a course for the treatment of;
Three, efficacy assessment standard adopts self treatment front and back symptom contrast;
The disappearance of produce effects clinical symptoms, liver function and blood fat index are normal;
The improvement of effective clinical symptom, liver function and blood fat index approach normal;
Invalid clinical symptoms do not have improvement, liver function and blood fat index undesired. Through observing, after the course for the treatment of of taking medicine, in the 100 routine sufferers, obvious effective rate reaches 32%, efficiently reaches 68%, and inefficiency is 0, and total effective rate is 100%.
Claims (2)
1. a Chinese medicine composition for the treatment of hepatitis is characterized in that, is made by the raw material of following weight portion: 1～4 part of Fructus Crataegi extract, and 4～16 parts of Lentinus Edodes extract,
Its preparation method is:
(1) gets clean mushroom fruiting body, be ground into the fritter grain, through tap water flushing dust, throw to extracting still, add the water that Lentinus Edodes weight 15-25 doubly measures, heating up is heated to 100 ℃ of extractions, extract after 3 hours-6 hours and stop, be cooled to room temperature, discharging, liquid-solid separation, clear liquid is delivered to concentrated post and is concentrated into 3～4 times of Lentinus Edodes weight, filtering residue adds the water that 15-12 doubly measures again, repeats the said extracted condition and extracts below 6 times, and filtering residue is abandoned it, supernatant merges the 3-5 times of concentrated solution that is concentrated into mushroom fruiting body weight, at room temperature, under the stirring condition, the 2-4 that adds the concentrated solution volume doubly measures medicinal alcohol, continues to stir 20 minutes-40 minutes, after static 10 hours-14 hours, separation of supernatant reclaims ethanol, and the precipitation material is after centrifuge is centrifugal, add 1-3 and doubly measure medicinal alcohol, blend washing, again after centrifuge is centrifugal, 40 ℃ of-80 ℃ of vacuum dryings of centrifugal material drying machine, discharging, pulverize, with 60 orders/time sub-sieve sieve, promptly get Lentinus Edodes extract after the weighing;
(2) Fructus Crataegi of learning from else's experience and cutting into slices adds 8-12 times of water of Fructus Crataegi weight, decocts 2 times-4 times, each 1 hour-3 hours, collecting decoction filters, and placing spends the night makes precipitation, getting supernatant concentrates to concentrating the post, 40 ℃ of-80 ℃ of vacuum dryings of drying machine, discharging is pulverized, with 60 orders/time sub-sieve sieve, promptly get Fructus Crataegi extract;
(3) get 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract add microcrystalline Cellulose 90-110 part, lactose 40-60 part, and magnesium stearate 1-3 part, carboxymethyl starch sodium 3-6 part, mixing, the system granule, tabletting promptly gets tablet;
(4) or 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract add microcrystalline Cellulose 90-110 part, lactose 40-60 part, and magnesium stearate 1-3 part, mixing, the system granule is filled, and promptly gets capsule;
(5) or 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract add dextrin 90-110 part, mixing, and the system granule promptly gets granule;
(6) or 1～4 part of Fructus Crataegi extract, 4～16 parts of Lentinus Edodes extract add water 90-110 part, acesulfame-K 1-3 part, and mixing, fill promptly gets oral liquid.
2. a kind of Chinese medicine composition for the treatment of hepatitis according to claim 1 is characterized in that described microcrystalline Cellulose is microcrystalline Cellulose PH102.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710037338A CN101057901B (en) | 2007-02-09 | 2007-02-09 | Traditional Chinese medicinal composition for curing hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710037338A CN101057901B (en) | 2007-02-09 | 2007-02-09 | Traditional Chinese medicinal composition for curing hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101057901A CN101057901A (en) | 2007-10-24 |
| CN101057901B true CN101057901B (en) | 2010-05-19 |
Family
ID=38864304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710037338A Expired - Fee Related CN101057901B (en) | 2007-02-09 | 2007-02-09 | Traditional Chinese medicinal composition for curing hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101057901B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138297A (en) * | 2015-04-27 | 2016-11-23 | 张磊 | Prevent and treat compositions and the application thereof of hepatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1214884A (en) * | 1997-10-20 | 1999-04-28 | 高志名 | Glossy ganoderma and lentinus edodes beverage |
-
2007
- 2007-02-09 CN CN200710037338A patent/CN101057901B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1214884A (en) * | 1997-10-20 | 1999-04-28 | 高志名 | Glossy ganoderma and lentinus edodes beverage |
Non-Patent Citations (3)
| Title |
|---|
| 丁建德.保肝精在肝硬化腹水治疗中增效作用的观察.山西中医12 6.1996,12(6),45-46. |
| 韩树颖 |
| 韩树颖;丁建德.保肝精在肝硬化腹水治疗中增效作用的观察.山西中医12 6.1996,12(6),45-46. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101057901A (en) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN103027138A (en) | Tea for enlivening spleens and production method of tea | |
| CN103027155A (en) | Mulberry leaf lipid-reducing pressure-reducing health-care tea and preparation method thereof | |
| CN102198262A (en) | Chinese medicine preparation for treating infant rotavirus enteritis and preparation method thereof | |
| CN102895320A (en) | Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout | |
| CN102772781A (en) | Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof | |
| CN100525791C (en) | Health product and medicine and their preparing method | |
| CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN103735943A (en) | Medicament composition for treating diarrhea and preparation method and application thereof | |
| CN101099844A (en) | Compound for spleen-strengthening and kidney-nourishing preparation and preparing method | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN102726557A (en) | Food possessing auxiliary hypolipidemic function | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN101057901B (en) | Traditional Chinese medicinal composition for curing hepatitis | |
| CN101011457A (en) | Traditional Chinese medicine composition with immunological enhancement function | |
| CN102726589A (en) | Chewing gum specially for diabetic patients and preparation method thereof | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN101019945B (en) | Hepatitis treating Chinese medicine composition soft capsule | |
| CN103340991B (en) | Oral liquid for nursing diabetics and preparation method thereof | |
| CN103525640B (en) | Energy-keeping yang-tonifying wine | |
| CN102698185B (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN104606571A (en) | Fresh spinach root tea substituted drink with effects of helping produce saliva and slaking thirst and preparation method thereof | |
| CN105031248A (en) | Health care product which contains Se-enriched cordyceps and is capable of assisting in blood sugar level regulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 200240 Shanghai city Minhang District Jianchuan road 951 block A No. 2 Patentee after: Shanghai pharmaceutical Polytron Technologies Inc Address before: 200240 Shanghai city Minhang District Jianchuan road 951 block A No. 2 Patentee before: Shanghai Cirui Pharmaceutical Sci. & Tech. Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20210209 |